Abstract
Preliminary results of our study suggest that mycophenolate mofetil (MMF) might be a useful treatment in patients who have failed or could not tolerate conventional immunosuppressive therapy for chronic graft-versus-host disease (GVHD). In addition, the favorable toxicity profile and steroid-sparing effect of MMF may be particularly attractive features of this medication.
Original language | English |
---|---|
Pages (from-to) | 837-839 |
Number of pages | 3 |
Journal | Haematologica |
Volume | 88 |
Issue number | 7 |
Publication status | Published - Jul 1 2003 |
ASJC Scopus subject areas
- Hematology